ClinicalTrials.gg
CompletedNCT05642325SandcatUpdated Apr 17, 2026

Vamikibart in Participants With Uveitic Macular Edema

A Phase 3 interventional study of Vamikibart and Sham in Uveitic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 94 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.

Enrollment
14th of 25
256 · median 377
Started
2023
with 1 other
Phase 3
14 of 28
none open now
Registered
21st of 28
by date

Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 14th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2023, is one of 14 in phase 3, and was the 21st registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Macular Edema by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

03

Conditions studied

  • Uveitic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants: Agreement to remain abstinent (refrain from heterosexual intercourse) or use as defined by the protocol
  • Diagnosis of macular edema associated with non-infectious uveitis (NIU)
  • Diagnosis of active or inactive, acute, or chronic NIU of any etiology and of any anatomical type (anterior, intermediate, posterior, panuveitis)
  • BCVA letter score of 73 to 19 letters (inclusive) on Early Treatment Diabetic Retinopathy Study (EDTRS)-like charts

Exclusion criteria

Exclusion Criteria:

  • Evidence of active or latent syphilis infection
  • Evidence of active or latent tuberculosis infection and/or positive tuberculosis assay, or previous or current diagnosis
  • Serious acute or chronic medical or psychiatric illness
  • History of major ocular and non-ocular surgical procedures
  • Uncontrolled IOP or glaucoma or chronic hypotony
  • Any anatomical changes or media opacity in the study eye preventing evaluation of retina, vitreous, and capture of study images
  • Prior use of IVT biologics including anti-VEGFs less than 2-4 months prior to Day 1; received IVT Methotrexate within 4 months prior to Day 1
  • Prior macular laser therapy, cataract surgery within 6 months and laser capsulotomy within 3 months of Day 1
  • Topical and/or topical NSAID > 3 drops per day in the 14 days prior to Day 1 (D1); intraocular or periocular corticosteroid injections in the 2 months prior to D1; subconjunctival corticosteroid injection within 1 month prior to Day 1; an OZURDEX implant in the 4 months prior to D1; YUTIQ, RETISERT or ILUVIEN implant in the 3 years prior to D1
  • Diagnosis of macular edema due to any cause other than NIU
  • Any major ocular conditions that may require medical or surgical intervention during the study period to prevent vision loss
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Arm A

    Participants will receive 4 high-dose vamikibart intravitreal (IVT) injections every 4 weeks (Q4W) to Week 12, followed by as-needed (PRN) dosing from Week 20 to Week 48.

    Drug: Vamikibart

  • Experimental
    Arm B

    Participants will receive 4 low-dose vamikibart IVT injections Q4W to Week 12, followed by PRN dosing from Week 20 to Week 48.

    Drug: Vamikibart

  • Sham comparator
    Arm C

    Participants will receive 4 sham injections Q4W to Week 12, followed by PRN sham dosing from Week 20 to Week 48.

    Other: Sham

Interventions

  • Participants will receive vamikibart IVT injection

    Also known as: RO7200220

  • OtherSham

    Participants will receive a sham procedure that mimics an IVT injection.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with ≥ 15 letter improvement from baseline in best-corrected visual acuity (BCVA) at Week 16

    Time frame: Week 16

Secondary outcomes

  1. Proportion of participants with ≥ 15 letter improvement from baseline in BCVA at Week 20

    Time frame: Week 20

  2. Change from baseline in BCVA at Week 16

    Time frame: Week 16

  3. Change from baseline in central subfield thickness (CST) at Week 16

    Time frame: Week 16

  4. Change from Baseline in BCVA at Weeks 20 and 52

    Time frame: Weeks 20 and 52

  5. Change from baseline in CST at Weeks 20 and 52

    Time frame: Weeks 20 and 52

  6. Proportion of participants with uveitic macular edema secondary to non-infectious uveitis (UME) resolution defined by standardized (by machine) CST threshold <325um on optical coherence tomography (OCT) from baseline at Weeks 16 and 52

    Time frame: Weeks 16 and 52

  7. Time to rescue treatment

    Time frame: Up to Week 52

  8. Number of rescue treatments received

    Time frame: Up to Week 52

  9. Type of rescue treatments received

    Time frame: Up to Week 52

  10. Proportion of participants with ≥15 letter improvement from baseline in BCVA at Week 16 and 52

    Time frame: Weeks 16 and 52

  11. Proportion of participants without ≥15 letter loss from baseline in BCVA at Week 16 and 52

    Time frame: Weeks 16 and 52

  12. Time to first PRN injection

    Time frame: Up to Week 52

  13. Change from baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) at Weeks 16 and 52

    Time frame: Weeks 16 and 52

  14. Percentage of participants with ocular adverse events (AEs)

    Time frame: Up to Week 52

  15. Percent change from baseline in corneal endothelial cell density at Week 24

    Time frame: Week 24

  16. Percentage of participants with non-ocular AEs

    Time frame: Up to Week 52

  17. Percentage of participants with adverse events of special interest (AESIs)

    Time frame: Up to Week 52

  18. Percent change from baseline in corneal endothelial cell density at Week 52

    Time frame: Week 52

  19. Aqueous humor (AH) concentration of vamikibart

    Time frame: Up to Week 52

  20. Serum concentration of vamikibart

    Time frame: Up to Week 52

  21. Anti-drug antibody titer to vamikibart

    Time frame: Baseline to Week 52

07

Study locations

94 sites
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • Barnet Dulaney Perkins Eye Center
    Sun City, Arizona 85351, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • California Eye Specialists Medical group Inc.
    Pasadena, California 91107, United States
  • Retina Consultants of Southern California
    Redlands, California 92374, United States
  • Kaiser Permanente Riverside Medical Center
    Riverside, California 92505, United States
  • University of California, Davis, Eye Center
    Sacramento, California 95817, United States
  • Retinal Consultants Med Group
    Sacramento, California 95825, United States
  • Advanced Research
    Deerfield Beach, Florida 33064, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • University Retina and Macula Associates, PC
    Oak Forest, Illinois 60452, United States
  • Cumberland Valley Retina PC
    Hagerstown, Maryland 21740, United States
  • University of Michigan, Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
  • Duke Eye Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Erie Retina Research
    Erie, Pennsylvania 16507-1429, United States
  • Mid Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Retina Consultants of Texas
    Katy, Texas 77494, United States
  • Retina Group of Washington
    Fairfax, Virginia 22031, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Centro Privado de Ojos
    Ciudad Autonoma Buenos Aires, C1033AAW, Argentina
  • Buenos Aires Mácula
    Ciudad Autonoma Buenos Aires, C1061AAE, Argentina
  • Consultorios Medicos Oftalmológicos
    Ciudad Autonoma Buenos Aires, C1426DQS, Argentina
  • Oftalmologia Global
    Rosario, 2000, Argentina
  • Organizacion Medica de Investigacion
    San Nicolás, C1015ABO, Argentina
  • Sydney Eye Hospital
    Sydney, New South Wales 2000, Australia
  • Centre For Eye Research Australia
    East Melbourne, Victoria 3002, Australia
  • Eye Surgery Associates
    Malvern, Victoria 3144, Australia
  • Retina Specialists Victoria
    Rowville, Victoria 3178, Australia
  • The Lions Eye Institute
    Nedlands, Western Australia 6009, Australia
  • Peking Union Medical College Hospital
    Beijing, 100032, China
  • Beijing Tongren Hospital
    Beijing, 100730, China
  • The First Affiliated Hospital, Chongqing Medical University
    Chongqing, 400016, China
  • General Teaching Hospital Prague
    Prague, 128 08, Czechia
  • CHU Nantes - Hotel Dieu
    Nantes, 44093, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • Hôpital COCHIN
    Paris, 75014, France
  • Ch Pitie Salpetriere
    Paris, 75651, France
  • Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum
    Berlin, 13353, Germany
  • Universitatsklinikum Koln
    Cologne, 50937, Germany
  • Universitätsklinikum Freiburg, Klinik für Augenheilkunde
    Freiburg im Breisgau, 79106, Germany
  • Universitätsmedizin Göttingen Georg-August-Universität
    Göttingen, 37075, Germany
  • Universitatsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitätsklinik Heidelberg
    Heidelberg, 69120, Germany
  • Universitätskliniikum Schleswig-Holstein, Campus Lübeck
    Lübeck, 23538, Germany
  • St. Franziskus Hospital
    Münster, 48145, Germany
  • Knappschaftsklinikum Saar GmbH
    Sulzbach, 66280, Germany
  • Universitäts-Augenklinik Tübingen
    Tübingen, 72076, Germany
  • Narayana Nethralaya Hospital
    Bangalore, Karnataka 560010, India
  • Sankara Nethralaya
    Chennai, Tamil Nadu 600006, India
  • L V Prasad Eye Institute
    Hyderabad, Telangana 500034, India
  • ICARE Eye Hospital & PG Institute
    Noida, Uttar Pradesh 201301, India
  • Postgraduate Institute of Medical Education and Research
    Chandigarh, 160012, India
  • AUSL ? IRCCS Santa Maria Nuova
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • Irccs Ospedale San Raffaele
    Milan, Lombardy 20132, Italy
  • Asst Fatebenefratelli Sacco
    Milan, Lombardy 20157, Italy
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • Hiroshima University Hospital
    Hiroshima, 734-8551, Japan
  • Hokkaido University Hospital
    Hokkaido, 060-8648, Japan
  • Kobe University Hospital
    Hyōgo, 650-0017, Japan
  • Kagoshima University Hospital
    Kagoshima, 890-8520, Japan
  • Yokohama City University Hospital
    Kanagawa, 236-0004, Japan
  • Japan Community Health care Organization Osaka Hospital
    Osaka, 553-0003, Japan
  • The University of Osaka Hospital
    Osaka, 565-0871, Japan
  • Jichi Medical University Saitama Medical Center
    Saitama, 330-0834, Japan
  • National Defense Medical College Hospital
    Saitama, 359-8513, Japan
  • Tokyo Medical University Hospital
    Tokyo, 160-0023, Japan
  • Kyorin University Hospital
    Tokyo, 181-8611, Japan
  • Nippon Medical School Tama Nagayama Hospital
    Tokyo, 206-8512, Japan
  • Yamaguchi University Hospital
    Yamaguchi, 755-8505, Japan
  • "Kazakh "Badge of H?nour" Scientific R?s??r?h Institute of ??? diseases" LLP
    Almaty, 050012, Kazakhstan
  • AIBILI - Association for Innovation and Biomedical Research on Light
    Coimbra, 3000-548, Portugal
  • Hospital de Santa Maria
    Lisbon, 1649-035, Portugal
  • National University Hospital
    Singapore, 119074, Singapore
  • Pusan National University Hospital
    Busan, 602-739, South Korea
  • Kyung Hee University Hospital
    Seoul, 02447, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Hospital Universitari de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 8907, Spain
  • Hospital de Cruces
    Barakaldo, Vizcaya 48903, Spain
  • Hospital Clinic Barcelona
    Barcelona, 08036, Spain
  • Fundacion Jimenez Diaz-UTE
    Madrid, 28040, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Inselspital Bern Ophthalmologische Klinik
    Bern, 3010, Switzerland
  • Berner Augenklinik
    Bern, Switzerland
  • Vista Klinik Ophthalmologische Klinik
    Binningen, 4102, Switzerland
  • Stadtspital Triemli Ophthalmologische Klinik
    Zurich, 8063, Switzerland
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Chang Gung Medical Foundation - Linkou
    Taoyuan, 333, Taiwan
  • Hacettepe University Medical Faculty
    Ankara, 06100, Turkey (Türkiye)
  • Ege Üniversitesi Tip Fakültesi
    Lzmir, 35100, Turkey (Türkiye)
  • Moorfields Eye Hospital NHS Foundation Trust
    London, EC1V 2PD, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in May 2025, 25 months.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 25 months is close to that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2022
First posted
Dec 8, 2022
StartActual
Mar 23, 2023
Primary completionActual
May 7, 2025
CompletionActual
Dec 24, 2025
Results delay requested
Apr 10, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05642325
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Mar 23, 2023
Primary completion
May 7, 2025
Completion
Dec 24, 2025
Last update
Apr 17, 2026

Study contacts

Clinical Trials
study director · Hoffmann-LaRoche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vamikibart

Start the discussion